Table 1.
Baseline demographics and clinical characteristics of healthy participants (part A) and patients with psoriasis (part B)
| Part A: Healthy participants (N = 40) | Placebo (n = 14) | GSK2831781 | ||||
|---|---|---|---|---|---|---|
| 0.0003 mg/kg (n = 1) | 0.0015 mg/kg (n = 1) | 0.0075 mg/kg (n = 6) | 0.04 mg/kg (n = 6) | 0.15 mg/kg (n = 12) | ||
| Age, years, mean (SD) | 46.4 (12.3) | 21.0 (−) | 53.0 (−) | 46.7 (20.8) | 39.7 (12.5) | 50.7 (10.1) |
| Male, n (%) | 14 (100) | 1 (100) | 1 (100) | 6 (100) | 6 (100) | 12 (100) |
| Weight, kg, mean (SD) | 85.5 (9.6) | 70.7 (−) | 87.0 (−) | 84.2 (10.8) | 82.6 (12.0) | 79.2 (8.9) |
| Part B: Patients with psoriasis (N = 27) | Placebo (n = 9) | GSK2831781 | ||
|---|---|---|---|---|
| 0.5 mg/kg (n = 6) | 1.5 mg/kg (n = 6) | 5 mg/kg (n = 6) | ||
| Age, years, mean (SD) | 45.3 (13.1) | 47.2 (8.2) | 48.5 (13.6) | 51.8 (5.4) |
| Male, n (%) | 5 (56.0) | 6 (100) | 5 (83.0) | 5 (83.0) |
| Weight, kg, mean (SD) | 76.9 (14.6) | 88.7 (15.3) | 83.6 (12.0) | 94.4 (10.4) |
| PLSS, mean (SD) | 7.1 (1.1) | 6.5 (1.4) | 7.7 (1.4) | 6.5 (0.8) |
| PASI, mean (SD) | 10.3 (4.5) | 6.8 (2.4) | 14.1 (6.6) | 9.2 (4.1) |
| Total BSA, mean (SD) | 12.7 (8.9) | 6.7 (5.0) | 18.2 (10.5) | 10.7 (6.9) |
BSA, body surface area; PASI, Psoriasis Area Severity Index; PLSS, Psoriasis Lesion Severity Score.